Pacific Edge at risk of losing ‘significant’ revenue stream

Pacific Edge at risk of losing ‘significant’ revenue stream
The test has been used more than 10,000 times since it was first approved in 2020. (Image: Pacific Edge)
Dan Brunskill
Pacific Edge could have its cancer tests dropped by a major US health insurance company which is considering a new way to choose which tests are covered.  Medicare provider Novitas currently reimburses the use of Cxbladder but would not under a new process it has proposed. Currently, the health insurer reviews clinical evidence for each individual product but has proposed relying on third-party lists instead. Pacific Edge said if the proposal was adopted, Cxbladder would no longer receive reimbursement from Novitas, which makes up &ld...

More Markets

Freightways outlook and Fonterra vote drive upbeat day
Markets Market Close

Freightways outlook and Fonterra vote drive upbeat day

Freightways shares climbed after Mark Troughear flagged easing economic headwinds.

Tom Raynel 30 Oct 2025
Me Today raises funds to be here tomorrow
Markets

Me Today raises funds to be here tomorrow

Shareholders have approved a capital raise of up to $2.59 million.

Greg Hurrell 30 Oct 2025